HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.

AuthorsSangeetha Venugopal, Abhishek Maiti, Courtney D DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi, Naval G Daver, Tapan M Kadia, Caitlin R Rausch, Yesid Alvarado, Maro Ohanian, Koji Sasaki, Nicholas J Short, Koichi Takahashi, Musa Yilmaz, Farhad Ravandi, Hagop M Kantarjian, Marina Y Konopleva
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 62 Issue 14 Pg. 3501-3505 (12 2021) ISSN: 1029-2403 [Electronic] United States
PMID34474640 (Publication Type: Letter, Research Support, N.I.H., Extramural)
Chemical References
  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • Decitabine
  • Azacitidine
  • venetoclax
Topics
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Azacitidine (therapeutic use)
  • Bridged Bicyclo Compounds, Heterocyclic (adverse effects)
  • Cytogenetic Analysis
  • Decitabine (therapeutic use)
  • Humans
  • Leukemia, Myeloid, Acute (diagnosis, drug therapy, genetics)
  • Prognosis
  • Sulfonamides

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: